hello@eolasmedical.com
Estimated annual value of Eolas
Inputs used
| Staffed beds | 1,000 |
| Annual inpatient admissions | 50,000 |
| Annual antimicrobial drug spend | $6,500,000 |
| Annual C. difficile (CDI) cases | 200 |
| AMS pharmacist FTEs | 2 |
| Scenario | Base |
Value levers
| Antimicrobial drug spend¹ | $325,000 |
| Length of stay² | $1,402,500 |
| C. difficile cost avoidance³ | $300,000 |
| Adverse drug event avoidance⁴ | $300,000 |
| Estimated total cost savings | $2,327,500 |
≈ $2,328 per staffed bed per year. Hard-dollar levers only.
- Antimicrobial drug spend$325,00014%
- Length of stay$1,402,50060%
- C. difficile cost avoidance$300,00013%
- Adverse drug event avoidance$300,00013%
Assumptions
¹ Drug spend: antimicrobial spend × 5%. Published stewardship programs report 10–20% reductions in antimicrobial expenditure; Eolas is attributed conservatively at 3–8%.
² Length of stay: admissions × 34% receiving an antimicrobial course × 3% avoided bed day × $2,750 marginal bed-day cost.
³ CDI: cases × 10% × $15,000 attributable cost per case. CMS HAC Reduction Program exposure is not included.
⁴ Adverse drug events: fixed $300,000 for this scenario. In a peer-reviewed simulation study in npj Antimicrobials and Resistance (Nature Portfolio, 2026), Ask Eolas achieved 100% prescribing accuracy vs 47% with standard PDF guidelines (NNT 1.9, p < 0.001) in a controlled simulation.
Illustrative model using published US benchmarks. We refine every assumption with your own data during evaluation, including a baseline of your NHSN antibiotic-use data so results are measured, not modelled.
Your health system
Everything recalculates as you move — nothing is submitted or stored.
Estimated total cost savings
≈ $2,328 per staffed bed per year
Stewardship capacity: your 2 AMS pharmacists influence ~17,000 antimicrobial courses a year — Eolas is the force multiplier.
Hard-dollar levers only. Clinician time savings and survey-readiness value are additional.
Antimicrobial drug spend¹
A 5% reduction in what you spend on antimicrobials, from better first-choice prescribing.
Length of stay²
Earlier, guideline-concordant IV-to-oral switches free up bed days worth $2,750 each.
C. difficile cost avoidance³
Fewer days of broad-spectrum exposure means 10% fewer CDI cases at ~$15,000 each.
Adverse drug event avoidance⁴
A conservative translation of the prescribing-error reduction measured in a controlled simulation.
Where the estimated value comes from
- Antimicrobial drug spend$325,00014%
- Length of stay$1,402,50060%
- C. difficile cost avoidance$300,00013%
- Adverse drug event avoidance$300,00013%
Illustrative model using published US benchmarks. We refine every assumption with your own data during evaluation.
Assumptions & sources
The whole model is open. Constants are fixed at published US benchmarks; only the scenario and your own numbers change.
Every figure here is a starting point, not a promise. The evaluation plan includes a baseline of your own NHSN antibiotic-use data so results are measured, not modelled.
The evidence behind the model
100% prescribing accuracy
Ask Eolas vs 47% with PDF guidelines, p < 0.001 — controlled simulation, Imperial College London, npj Antimicrobials and Resistance (2026)
NNT 1.9
One additional error-free prescription for every two clinicians who switch from PDFs to Ask Eolas
4× resource utilization
Carilion Clinic (6 hospitals, ~280 outpatient practices): 4-fold increase in stewardship resource access, sustained over four months
Up to 65% of inpatients
Up to 65% of admitted patients receive at least one antibiotic during their stay — so every prescribing decision, good or poor, scales across almost two-thirds of your census